I 

117TH CONGRESS 

1ST SESSION H. R. 1123 

To direct the Secretary of Veterans Affairs to conduct a review of the 

deaths of certain veterans who died by suicide, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 18, 2021 

Mr. GARBARINO (for himself, Mr. JOYCE of Ohio, Mr. AMODEI, Mr. KATKO, 

Mr. KILMER, Mrs. RADEWAGEN, Mr. RUSH, and Mr. WELCH) introduced 

the following bill; which was referred to the Committee on Veterans’ Affairs 

A BILL 

To direct the Secretary of Veterans Affairs to conduct a 

review of the deaths of certain veterans who died by 

suicide, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Veteran Suicide Pre5 vention Act’’. 

6 SEC. 2. DEPARTMENT OF VETERANS AFFAIRS REVIEW OF 

7 CERTAIN VETERANS’ DEATHS BY SUICIDE. 

8 (a) REVIEW REQUIRED.—Not later than 18 months 

9 after the date of the enactment of this Act, the Secretary 


khammond on DSKJM1Z7X2PROD with BILLS
2 

•HR 1123 IH

1 of Veterans Affairs shall complete a review of the deaths 

2 of all covered veterans who died by suicide during the five3 year period preceding the date of the enactment of this 

4 Act. Such review shall include— 

5 (1) the total number of veterans who died by 

6 suicide during the five-year period preceding the 

7 date of the enactment of this Act; 

8 (2) a summary of such veterans that includes 

9 the age, gender, and race of such veterans; 

10 (3) a comprehensive list of the medications pre11 scribed to, and found in the systems of, such vet12 erans at the time of their deaths, specifically listing 

13 any medications that carried a black box warning, 

14 were off-label, psychotropic, or carried warnings that 

15 included suicidal ideation; 

16 (4) a summary of medical diagnoses by Depart17 ment of Veterans Affairs physicians which led to the 

18 prescribing of the medications referred to in para19 graph (3); 

20 (5) the number of instances in which the vet21 eran who died by suicide was concurrently on mul22 tiple medications prescribed by Department of Vet23 erans Affairs physicians; 


khammond on DSKJM1Z7X2PROD with BILLS
3 

•HR 1123 IH

1 (6) the percentage of veterans who died by sui2 cide who were not taking any medication prescribed 

3 by a Department of Veterans Affairs physician; 

4 (7) the percentage of veterans referred to in 

5 paragraph (1) with combat experience or trauma 

6 (including, but not limited to military sexual trauma, 

7 traumatic brain injury, and post-traumatic stress); 

8 (8) Veteran Health Administration facilities 

9 with markedly high prescription and suicide rates of 

10 patients being treated at those facilities; 

11 (9) a description of Department of Veterans Af12 fairs policies governing the prescribing of medica13 tions referred to in paragraph (3); 

14 (10) any patterns apparent to the Secretary 

15 based on the review; and 

16 (11) recommendations for further action that 

17 would improve the safety and well-being of veterans. 

18 (b) PUBLIC AVAILABILITY.—Not later than 30 days 

19 after the completion of the review required under sub20 section (a), the Secretary shall— 

21 (1) submit to Congress a report on the results 

22 of the review; and 

23 (2) make such report publicly available. 

24 (c) COVERED VETERAN.—In this section: 


khammond on DSKJM1Z7X2PROD with BILLS
4 

•HR 1123 IH

1 (1) The term ‘‘covered veteran’’ means any vet2 eran who received hospital care or medical services 

3 furnished by the Department of Veterans Affairs 

4 during the five-year period preceding the death of 

5 the veteran. 

6 (2) The term ‘‘black box warning’’means a 

7 warning displayed within a box in the prescribing in8 formation for drugs that have special problems, par9 ticularly ones that may lead to death or serious in10 jury. 

Æ 


khammond on DSKJM1Z7X2PROD with BILLS